全文获取类型
收费全文 | 20593篇 |
免费 | 1678篇 |
国内免费 | 528篇 |
专业分类
耳鼻咽喉 | 14篇 |
儿科学 | 2203篇 |
妇产科学 | 78篇 |
基础医学 | 1875篇 |
口腔科学 | 77篇 |
临床医学 | 2632篇 |
内科学 | 4757篇 |
皮肤病学 | 192篇 |
神经病学 | 177篇 |
特种医学 | 201篇 |
外国民族医学 | 5篇 |
外科学 | 249篇 |
综合类 | 2985篇 |
预防医学 | 418篇 |
眼科学 | 68篇 |
药学 | 1404篇 |
7篇 | |
中国医学 | 331篇 |
肿瘤学 | 5126篇 |
出版年
2023年 | 316篇 |
2022年 | 317篇 |
2021年 | 618篇 |
2020年 | 739篇 |
2019年 | 644篇 |
2018年 | 595篇 |
2017年 | 698篇 |
2016年 | 677篇 |
2015年 | 778篇 |
2014年 | 1267篇 |
2013年 | 1368篇 |
2012年 | 1033篇 |
2011年 | 1262篇 |
2010年 | 893篇 |
2009年 | 911篇 |
2008年 | 900篇 |
2007年 | 858篇 |
2006年 | 812篇 |
2005年 | 784篇 |
2004年 | 760篇 |
2003年 | 567篇 |
2002年 | 505篇 |
2001年 | 505篇 |
2000年 | 371篇 |
1999年 | 356篇 |
1998年 | 309篇 |
1997年 | 233篇 |
1996年 | 290篇 |
1995年 | 341篇 |
1994年 | 319篇 |
1993年 | 270篇 |
1992年 | 257篇 |
1991年 | 237篇 |
1990年 | 180篇 |
1989年 | 197篇 |
1988年 | 195篇 |
1987年 | 138篇 |
1986年 | 121篇 |
1985年 | 234篇 |
1984年 | 177篇 |
1983年 | 112篇 |
1982年 | 144篇 |
1981年 | 115篇 |
1980年 | 90篇 |
1979年 | 99篇 |
1978年 | 66篇 |
1977年 | 54篇 |
1976年 | 53篇 |
1975年 | 17篇 |
1974年 | 7篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
Disparity in Utilization of Multiagent Therapy for Acute Promyelocytic Leukemia in the United States
《Clinical Lymphoma, Myeloma & Leukemia》2022,22(5):319-325
BackgroundDespite high rate of cure in acute promyelocytic leukemia (APL) in clinical trials, outcomes in real-world practice are dismal. We utilized National Cancer Database (NCDB) to explore utilization of multiagent therapy in APL and identify any disparities in treatment in real-world practices.Patients and MethodsNCDB categorizes use of systemic chemotherapy into single agent versus multiagent therapy. Some patients received hormonal therapy, immunotherapy, and unknown therapy; details of these treatments could not be ascertained. We therefore used multiple logistic regression analysis to evaluate effects of covariates on the probability of multiagent therapy use in 6678 patients.ResultsCompared to patients >60 years, patients aged 0 to 18 years (hazard ratio[HR] 3.2, 95% confidence interval [CI] 1.8-5.5, P< .0001), 19 to 40 years (HR 1.6, 95% CI 1.03-2.54, P= .03), and 41 to 60 years (HR 1.6, 95% CI 1.3-1.9, P< .0001) were more likely to receive multiagent therapy. Patients with Charlson comorbidity index (CCI) of 0 (HR 1.6, 95% CI 1.2-2.3, P= .001) and CCI of 1 (HR 1.4, 95% CI 1.0-1.9, P= .04) had a higher likelihood of receiving multiagent therapy than patients with CCI ≥ 3. Patients treated at academic cancer centers, compared to those treated at community cancer center (HR 0.5, 95% CI 0.3-0.7, P= .001), comprehensive community cancer center (HR 0.7, 95% CI 0.6-0.8, P< .0001), and integrated network cancer center (HR 0.8, 95% CI 0.6-0.9, P= .02) were more likely to be treated with multiagent therapy. Compared to the patients with private insurance, those with Medicaid had increased likelihood (HR 1.2, 95% CI 1.0-1.4, P= .04) whereas uninsured patients had a lower likelihood of receiving multiagent therapy (HR 0.6, 95% CI 0.5-0.8, P= .0005).ConclusionTo our knowledge, this study is the first and the largest scale analysis of treatment practices in APL in real-world practices. Our findings highlight significant disparities in treatment of APL based on age, insurance, and health-system factors. 相似文献
3.
目的探讨口腔鳞状细胞癌(OSCC)组织中长链非编码RNA(lncRNA)淋巴细胞白血病缺失基因1(DLEU1)的表达及与临床病理参数和预后的关系。 方法收集2017年1月至2017年12月南通大学附属医院保存的98例OSCC组织及癌旁组织,实时荧光定量-聚合酶链式反应(qRT-PCR)检测癌组织和癌旁组织中lncRNA DLEU1表达。分析lncRNA DLEU1表达与OSCC患者临床病理参数的关系,K-M法绘制不同lncRNA DLEU1表达OSCC患者生存曲线,多因素Cox回归分析OSCC患者预后不良影响因素。 结果OSCC组织中lncRNA DLEU1表达(1.863±0.572)高于癌旁组织(1.058±0.211)(t=13.058,P<0.001)。lncRNA DLEU1表达与OSCC患者肿瘤区域淋巴结转移(TNM)分期、淋巴结转移有关(P<0.05)。中位随访26个月,lncRNA DLEU1≥1.863生存率为61.22%,低于lncRNA DLEU1<1.863的79.59%(Log-rank χ2=4.819,P=0.028)。TNM分期Ⅲ~Ⅳ期(HR=4.612,95%CI:1.482~11.352)、淋巴结转移(HR=4.370,95%CI:1.442~10.246)、lncRNA DLEU1≥1.863(HR=4.231,95%CI:1.350~10.260)是OSCC患者预后不良的独立风险因素(P<0.05)。 结论OSCC组织中lncRNA DLEU1高表达,与TNM分期、淋巴结转移和预后相关,可能成为新的OSCC诊治和预后分子标志物。 相似文献
4.
5.
目的 采用两样本孟德尔随机化研究方法探讨血清生长分化因子15(GDF15)水平与慢性淋巴细胞白血病(CLL)发生之间的关联。方法 基于欧洲人群血清GDF15和CLL的全基因组关联研究公开数据库,筛选与血清GDF15水平相关的遗传变异位点作为工具变量,采用逆方差加权法评估遗传学预测的血清GDF15浓度与CLL发生的关联,采用最大似然比法进行敏感性分析,采用MR-Egger回归探讨工具变量潜在多效性。结果 研究共纳入3个单核苷酸多态位点作为工具变量,逆方差加权法结果显示,血清GDF15水平与CLL发生风险之间存在负相关,GDF15浓度每升高一个标准差(SD),CLL发生风险降低33%(95%置信区间:2%~54%)(P=0.039)。敏感性分析得到了一致的结果。此外,MR-Egger回归未发现存在多效性。结论 本研究结果提示,在欧洲人群中,血清GDF15水平与CLL发生之间可能存在负相关,仍需大样本人群研究及体内外实验进一步阐明GDF15在CLL发生发展中的作用及其潜在生物学机制。 相似文献
6.
目的 探讨外周血单核细胞髓样分化因子88(My D88)与Toll样受体4(TLR4)在早产儿窒息后多器官功能障碍综合征(MODS)中的表达,为早产儿窒息后MODS的早期诊断及预后评估提供新思路。方法 连续性纳入2019年1月-2020年12月唐山市妇幼保健院新生儿科收治的115例窒息早产儿进行前瞻性研究,按照1 min Apgar评分将窒息早产儿分为轻度窒息组(n=70)与重度窒息组(n=45),以同期的50例健康早产儿作为对照组。比较3组早产儿中MODS发生率、MODS病死率及单器官损害发生率,外周血单核细胞My D88 mRNA及蛋白与TLR4 mRNA及蛋白的表达水平。结果 重度窒息组、轻度窒息组与对照组的MODS发生率分别为73.33%、31.43%、6.00%,MODS病死率分别为24.44%、5.71%、0,3组间比较差异有统计学意义(χ2=47.845、16.978,P<0.001);重度窒息组与轻度窒息组的单器官损害发生率明显高于对照组(P<0.05),重度窒息组明显高于轻度窒息组(P<0.05);重度窒息组与轻度窒息组的My D88 mRNA及蛋白与TLR4 mRNA及蛋白均明显高于对照组,且重度窒息组明显高于轻度窒息组(F=4.251、4.804、4.772、4.690,P<0.001)。结论 早产儿窒息后MODS发生率、外周血单核细胞My D88与TLR4表达水平均明显增高,My D88与TLR4有望成为早产儿窒息后MODS的早期诊断及预后评估指标。 相似文献
7.
《Vaccine》2022,40(30):4038-4045
PurposeAs protection from COVID-19 following two doses of the BNT162b2 vaccine showed a time dependent waning, a third (booster) dose was administrated. This study aims to compare the antibody response following the third dose versus the second and to evaluate post-booster seroconversion.MethodsA prospective observational study conducted in Maccabi Healthcare Services. Serial SARS-CoV-2 Spike IgG tests, 1,2,3 and 6 months following the second vaccine dose and one month following the third were obtained. Neutralizing antibody levels were measured in a subset of participants. Per individual SARS-CoV-2 Spike IgG titer ratios were calculated one month after the booster administration compared to titers one month following the second dose and prior to booster.ResultsAmong 110 participants, 56 (51%) were women. Mean age was 61.7 ± 1.9 years and 66 (60%) were immunocompromised. One month after third dose, IgG titers were induced 7.83 (95 %CI 5.25–11.67) folds and 2.40 (95 %CI 1.90–3.03) folds compared to one month after the second, in the immunocompromised and immunocompetent groups, respectively. Of the 17 immunocompromised participants who were seronegative after the second dose, 4 (24%) became seropositive following the third. Comparing the titers prior to the third dose, an increase of 50.7 (95 %CI 32.5–79.1) fold in the immunocompromised group and 25.7 (95 %CI 19.1–34.7) fold in and immunocompetent group, was observed.ConclusionA third BNT162b2 vaccine elicited robust humoral response, superior to the response observed following the second, among immunocompetent and immunocompromised individuals. 相似文献
8.
《Clínica e investigación en ginecología y obstetricia》2022,49(2):100734
Acute myeloid leukaemia (AML) is one of the deadliest haematological malignancies. During pregnancy it is a rare comorbidity and can lead to adverse outcomes, such as death, without adequate treatment. The management of AML during pregnancy remains a challenge. We report the case of a primigravida 34-year-old, with 18 weeks of amenorrhoea, who attended the emergency department presenting with pain and hypertrophy of the oral mucosa, accompanied by intense asthenia. Acute myeloblastic leukaemia was diagnosed. The possibility of terminating the pregnancy was offered given the lack of evidence regarding the maternal-foetal outcome, but the patient rejected it, so chemotherapy treatment was started. In the ultrasound controls there was no evidence of teratogenic alterations nor foetal growth restriction, and there were no alterations in Doppler flow values. It was decided to end the pregnancy at 32 + 3 GW. A preterm male was born through eutocic delivery with a normal Apgar test and umbilical cord pH, and did not require resuscitation. The puerperium was favourable and 15 days following discharge she was admitted for a bone marrow transplant from her HLA identical sister. The patient died due to rejection of the transplant and the complications derived from this event. 相似文献
9.
Dikshat Gopal Gupta PhD Neelam Varma MD Praveen Sharma MD Mihai I. Truica MD PhD Sarki A. Abdulkadir MD PhD Parmod Singh PhD Man Updesh Singh Sachdeva MD Shano Naseem MD Mohammad Rizwan Siddiqui PhD Parveen Bose MSc Jogeshwar Binota MSc Pankaj Malhotra MD Alka Khadwal MD Amita Trehan Subhash Varma MD 《Cancer》2023,129(21):3390-3404
10.
目的 探讨BCOR/BCORL1突变的髓系肿瘤患者的共突变基因表达谱,分析其病理参数及临床意义。方法 回顾性分析2017年1月至2021年8月在上海交通大学附属第一人民医院确诊的47例BCOR/BCORL1突变的髓系肿瘤患者。运用二代测序技术分析患者的基因共突变表达谱,采用两独立样本秩和检验分析BCOR/BCORL1突变患者病理参数之间的差异。通过Kaplan-Meier分析突变位置和治疗方法对患者无病生存(DFS)时间和总生存(OS)时间的影响。结果 急性髓系白血病(AML)患者以点突变为主(51.1%),骨髓增生异常综合征(MDS)和MDS/骨髓增殖性肿瘤(MPN)患者以移码突变、错义突变和无义突变为主(19.1%),二者分布差异具有统计学意义(χ2=7.458,P=0.006)。伴代谢酶组突变患者白细胞计数(Z=-3.500,P=0.018)、血小板计数(Z=82.500,P=0.027)、血浆纤维蛋白原(Fib)含量(Z=-0.935,P=0.008)和凝血酶时间(Z=0.800,P=0.027)与野生型患者相比差异均有统计学意义;伴甲基化组突变患者血浆F... 相似文献